Full Press Release Details
Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
Mass., December 27, 2023 -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a company
developing treatments for severe neurodegenerative diseases, today announced that it has received a notification from the Listing Qualifications
Department of the Nasdaq Stock Market LLC ("Nasdaq") advising the Company that it no longer satisfied the minimum $2.5 million
stockholders' equity requirement for continued listing on Nasdaq set forth in Nasdaq Listing Rule 5550(b)(1) (the "Minimum
Equity Rule") or, alternatively, the requirement that the Company either maintain a market value of listed securities of at least
$35 million or generate net income from continuing operations of $500,000 in the most recently completed fiscal year or two of the last
three most recently completed fiscal years.
notification from Nasdaq, received on December 21, 2023, has no immediate effect on NeuroSense's business or the listing or trading
of NeuroSense's ordinary shares which continue to trade on the Nasdaq Capital Market under the symbol "NRSN."
has 45 days from the date of the notice, or until February 5, 2024, to submit to Nasdaq a plan to regain compliance with the Minimum
Equity Rule or an alternative continued listing standard. If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar
days from the date of the notice, or until June 18, 2024, for the Company to regain compliance.
Ben-Noon, NeuroSense's CEO stated, "The recent positive results we received from our ALS Phase 2b clinical trial are highly
encouraging and have the potential to open new opportunities for the Company. We are currently working on a plan to submit to Nasdaq
and intend to regain compliance with Nasdaq's listing rules within the allotted timeframe. This notification does not affect our ongoing
operations or our commitment to advance PrimeC towards the market."
lateral sclerosis ("ALS") is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years
from diagnosis. Every year, more than 5,000 patients are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1
billion. The number of patients with ALS is expected to grow by 24% by 2040 in the U.S. and EU.
NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved
drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS that contribute to motor
neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit
the progression of ALS. NeuroSense completed the 6-month double blind portion of its Phase 2b ALS clinical trial which met its safety
and tolerability endpoints, as well as showing a statistically significant slowing of disease progression in the pre-specified Per Protocol
(PP) population. Additional data from the Phase 2b study are expected H1 2024. PrimeC was granted Orphan Drug Designation by the U.S.
Food and Drug Administration and the European Medicines Agency.
Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering
from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic
lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one
of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due
to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's
strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
additional information, we invite you to visit our website and
press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"
"could," "estimate," "expect," "intend," "seek," "may," "might,"
"plan," "potential," "predict," "project," "target," "aim," "should,"
"will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements
contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict and include statements regarding the Company's ability to regain
compliance with the Minimum Equity Rule or an alternative continued listing standard, the Company's ability to maintain the listing
of its ordinary shares on Nasdaq, PrimeC as a potential treatment for people with ALS, the timing for release of additional results from
PARADIGM clinical trial, and other regulatory milestones, the timing for release of results from the Company's strategic collaboration
with Biogen, the cash runway of the Company, the timing of a Phase 2 trial for Alzheimer's disease and patient enrollment regarding a
Phase 3 pivotal ALS trial of PrimeC. Further, certain forward-looking statements are based on assumptions as to future events that may
not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those
anticipated or implied in the forward looking statements. These risks include unexpected R&D costs or operating expenses, a delay
in the reporting of additional results from PARADIGM clinical trial; a delay in the reporting of results from the Company's strategic
collaboration with Biogen; the timing of expected regulatory and business milestones; risks associated with meeting with the FDA
to determine the best path forward following the results from PARADIGM clinical trial, including a delay in any such meeting; a delay
in patient enrollment for a Phase 2 trial for Alzheimer's disease or its planned Phase 3 pivotal ALS trial of PrimeC; the potential for
PrimeC to safely and effectively target ALS; preclinical and clinical data for PrimeC; the uncertainty regarding outcomes and the timing
of current and future clinical trials; timing for reporting data; the development and commercial potential of any product candidates
of the company; the success of steps taken to regain and maintain compliance with Nasdaq's continued listing standards; and other
risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission ("SEC"). You should
not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting the
Company is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the SEC on March 22, 2023
and the Company's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date,
and NeuroSense Therapeutics Ltd. undertakes no duty to update such information except as required under applicable law.
further information: Email: info@neurosense-tx.com, Tel: +972 (0)9 799 6183